Chronic Hypoparathyroidism: Conventional Therapy or the New Recombinant PTH
A single patient whose conventional therapy technically works but never lets her feel well. The disagreement is whether the only PTH-replacement option now available is worth reaching for, given real questions about how much benefit it adds.
Petronella W., a 45-year-old woman, developed permanent hypoparathyroidism after a total thyroidectomy for multinodular goiter four years ago — one of the small proportion of thyroidectomy patients whose parathyroid glands never recovered function. She has worked steadily with her endocrinologist since on a calcium and calcitriol regimen adjusted repeatedly over those four years, and describes life on it as a constant low-grade negotiation: tingling in her fingers and around her mouth when her calcium drifts down, and a kidney-stone scare eighteen months ago when a stretch of aggressive dosing to chase a low calcium pushed her urinary calcium too far the other way. She has never gone more than a few months without one swing or the other.
Her most recent corrected calcium, 7.8 mg/dL, was drawn during a routine follow-up rather than a symptomatic episode — which is the detail that matters, because a low value on a quiet day means the swings are not the exception her four-year record catches only at its edges. They are where she sits. Her adherence is documented as consistently good across those four years, so this is not a compliance problem; it is a limitation of what oral calcium and active vitamin D can replicate of normal parathyroid physiology, which is pulsatile and continuous in a way twice-daily tablets are not. Palopegteriparatide — a prodrug releasing PTH(1–34) continuously across a 24-hour dosing period — became the only PTH replacement in this class after Natpara's manufacturing-driven withdrawal at the end of 2024, and unlike her current regimen it supplies the hormone she lacks rather than working around its absence. Its pivotal evidence is narrower than the switch might imply: the phase 3 PaTHway trial randomized 84 patients over 26 weeks, and Canada's Drug Expert Committee, reviewing that evidence in 2025–2026, recommended reimbursement 15 to 0 while concluding it remains uncertain whether the drug demonstrates acceptable added clinical value over conventional therapy. Her own four-year record of swings sits underneath a recommendation-with-conditions, not a clean endorsement.
What the cost-effectiveness review does and doesn't settle
I'd transition her to palopegteriparatide. Her calcium swings between symptomatic hypocalcemia and hypercalciuria despite genuinely good adherence to a well-titrated regimen — that's not a dosing problem I can fix with more adjustment, it's a limitation of what calcium and calcitriol can replicate of normal PTH physiology. Palopegteriparatide replaces the actual missing hormone.
Before moving there, I'd want her to know what the review actually said. Canada's Drug Expert Committee looked at this in 2025–2026 and voted 15 to 0 to recommend reimbursement — but with conditions, and while explicitly concluding it is uncertain whether palopegteriparatide demonstrates acceptable added clinical value over conventional therapy. Both halves are the finding. It isn't a rejection, and it isn't an endorsement of added benefit.
I'd also flag the mechanics, because they're where this goes wrong in practice: her calcium and calcitriol come down in steps alongside the new drug, against serial calcium checks. They don't stop the day she starts.
I don't think the review's finding and her situation are actually in conflict. A population-level cost-effectiveness review answers a different question than "has conventional therapy failed this specific patient." It's built to judge value for a typical patient on average, not to override an individual treatment failure like hers.
Her recurrent symptomatic swings despite good adherence are exactly the kind of individual pattern those population-level reviews aren't designed to capture case by case — the honest approach is to disclose the review's finding to her directly, alongside her own documented failure on conventional therapy, and let her weigh both.
Agreed: offer palopegteriparatide with full disclosure of both her own documented treatment failure on conventional therapy and the CDEC review's split finding — a 15-to-0 conditional reimbursement recommendation alongside an explicit statement that added clinical value over conventional therapy is uncertain — and, if she accepts, wean her calcium and calcitriol stepwise against serial calcium measurement rather than stopping them at initiation.
Not agreed, and explicitly left unresolved: whether the cost-effectiveness question should carry as much weight as it did in this conversation once set against an individual patient's repeated symptomatic swings — the clinical pharmacologist and second endocrinologist held different views on how much a population-level review should shape one patient's specific decision, and neither treated the other's position as settled by this case alone.